Protocol for a systematic review and meta-analysis of Kang-ai injection for patients with oesophageal cancer
- PMID: 32899102
- PMCID: PMC7478825
- DOI: 10.1097/MD.0000000000022148
Protocol for a systematic review and meta-analysis of Kang-ai injection for patients with oesophageal cancer
Abstract
Background: Oesophageal cancer (OC) is the sixth leading cause of cancer death worldwide. Despite the improvement of therapeutic methods in recent years, the prognosis of OC remains unsatisfactory. Kang-ai injection, a kind of traditional Chinese herbal medicine, has been widely applied as a promising adjunctive drug for OC. In this study, we aimed to summarize the efficacy and safety of Kang-ai injection for patients with advanced OC through the meta-analysis, in order to provide scientific reference for the design of future clinical trials.
Methods: Relevant randomized controlled trials and high-quality prospective cohort studies were searched from PubMed, Web of Science, Medline, Cochrane Library, Google Scholar, Excerpt Medica Database, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, China Scientific Journal Database and Wanfang Database. Papers in English or Chinese published from their inception to August 2020 will be included without any restrictions.Study selection and data extraction will be performed independently by 2 investigators. The clinical outcomes including overall response rate, disease control rate, overall survival, disease-free survival, quality of life, immune function and adverse events, were systematically evaluated. Stata 14.0 and Review Manager 5.3 were used for data synthesis, subgroup analysis, sensitivity analysis, meta regression, and risk of bias assessment.
Results: The results of this study will be published in a peer-reviewed journal, or presented the findings at a relevant conference.
Conclusion: Our study will draw an objective conclusion of the effects of Kang-ai injection combined with conventional treatment for advanced OC and provide a helpful evidence for clinicians to formulate the best postoperative adjuvant treatment strategy for OC patients.
Inplasy registration number: INPLASY202080019.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures
Similar articles
-
Xiaoaiping injection as adjunct therapy for patients with advanced esophageal carcinoma: A protocol for a systematic review and meta-analysis.Medicine (Baltimore). 2020 Jun 26;99(26):e20984. doi: 10.1097/MD.0000000000020984. Medicine (Baltimore). 2020. PMID: 32590810 Free PMC article.
-
Effect of Liuweiwuling tablet on biochemical and virological parameters, and quality of life in patients with hepatitis B virus-related cirrhosis: A protocol for a systematic review and meta-analysis.Medicine (Baltimore). 2020 Sep 11;99(37):e22065. doi: 10.1097/MD.0000000000022065. Medicine (Baltimore). 2020. PMID: 32925741 Free PMC article.
-
Brucea javanica oil emulsion injection (BJOEI) as an adjunctive therapy for patients with advanced colorectal carcinoma: A protocol for a systematic review and meta-analysis.Medicine (Baltimore). 2020 Jul 2;99(27):e21155. doi: 10.1097/MD.0000000000021155. Medicine (Baltimore). 2020. PMID: 32629751 Free PMC article.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Efficacy and Safety of Compound Kushen Injection for Advanced Colorectal Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials with Trial Sequential Analysis.Integr Cancer Ther. 2024 Jan-Dec;23:15347354241258458. doi: 10.1177/15347354241258458. Integr Cancer Ther. 2024. PMID: 38853681 Free PMC article.
Cited by
-
Efficacy and safety of Chinese patent medicine (Kang-ai injection) as an adjuvant in the treatment of patients with hepatocellular carcinoma: a meta-analysis.Pharm Biol. 2021 Dec;59(1):472-483. doi: 10.1080/13880209.2021.1915340. Pharm Biol. 2021. PMID: 33905666 Free PMC article.
-
The value of microRNA-203 as a biomarker for the prognosis of esophageal cancer: A protocol for systematic review and meta-analysis.Medicine (Baltimore). 2020 Dec 11;99(50):e23599. doi: 10.1097/MD.0000000000023599. Medicine (Baltimore). 2020. PMID: 33327325 Free PMC article.
-
Association between preoperative neutrophil-to-lymphocyte ratio and the survival outcomes of esophageal cancer patients underwent esophagectomy: a systematic review and meta-analysis.Front Oncol. 2024 Aug 19;14:1404711. doi: 10.3389/fonc.2024.1404711. eCollection 2024. Front Oncol. 2024. PMID: 39224809 Free PMC article. Review.
-
Traditional Chinese Medicine Therapy for Esophageal Cancer: A Literature Review.Integr Cancer Ther. 2021 Jan-Dec;20:15347354211061720. doi: 10.1177/15347354211061720. Integr Cancer Ther. 2021. PMID: 34825600 Free PMC article. Review.
-
Overcoming Basal Autophagy, Kangai Injection Enhances Cisplatin Cytotoxicity by Regulating FOXO3a-Dependent Autophagic Cell Death and Apoptosis in Human Lung Adenocarcinoma A549/DDP Cells.Biomed Res Int. 2022 Sep 1;2022:6022981. doi: 10.1155/2022/6022981. eCollection 2022. Biomed Res Int. 2022. PMID: 36093402 Free PMC article.
References
-
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.. - PubMed
-
- Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019;144:1941–53.. - PubMed
-
- Pera M. Recent changes in the epidemiology of esophageal cancer. Surg Oncol 2001;10:81–90.. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical